From Medscape Oncology

Coverage from the

American Association for Cancer Research (AACR) Annual Meeting 2023

April 14 - 19, 2023; Orlando, Florida and Virtual/Online

April 14 - 19, 2023 Orlando, Florida and Virtual/Online

AACR 2023 Drug Combo Improves Recurrence-Free Survival After HCC Resection The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.
Medscape Medical News, April 18, 2023
AACR 2023 'Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma Combining Moderna's patient-specific mRNA-based cancer vaccine with pembrolizumab may prolong recurrence-free survival in patients with high-risk melanoma vs pembrolizumab alone, new data show.
Medscape Medical News, April 17, 2023

Conference News

AACR 2023 AI Predicts Endometrial Cancer Recurrence
MDedge News, April 21, 2023
AACR 2023 African Ancestry Genetically Linked to Worse CRC Outcomes
Medscape Medical News, April 21, 2023
AACR 2023 ctDNA Promising for Cancer Detection, but Faces Challenges
MDedge News, April 21, 2023
AACR 2023 Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?
Medscape Medical News, April 20, 2023

AACR 2023 Bispecific Antibody Provides Durable Remission in Myeloma
Medscape Medical News, April 19, 2023
AACR 2023 Pembrolizumab Monotherapy Effective for Rare Melanoma
MDedge News, April 19, 2023
AACR 2023 Drug Combo Improves Recurrence-Free Survival After HCC Resection
Medscape Medical News, April 18, 2023
AACR 2023 'Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma
Medscape Medical News, April 17, 2023

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Advances in Breast Cancer From AACR 2023
Kathy D. Miller, MD
Key Takeaways in Early Breast Cancer From AACR 2023
Kathy D. Miller, MD

Popular News from AACR 2022

Recurrent DCIS Can Be Genetically Distinct From Primary Lesion In more than 10% of cases, when ductal carcinoma in situ recurs in the same breast, the new lesion is genetically district from the original lesion.
Medscape Medical News, Apr 11, 2022
Preop Nivolumab Plus Chemo 'a Quantum Leap' in NSCLC Therapy Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non–small cell lung cancer.
Medscape Medical News, Apr 12, 2022
'Truly Impressive' Responses in Lymphoma With Novel Cell Therapy Activated natural killer cells combined with a bispecific antibody showed strong activity in heavily pretreated patients with lymphoma expressing the CD30 antigen.
Medscape Medical News, Apr 11, 2022

Previous Coverage